Gilead Sciences (NASDAQ:GILD) Price Target & New Coverage by Deutsche Bank

Stock research analysts at Deutsche Bank started coverage on Gilead Sciences (NASDAQ:GILD) with “Buy” rating. The target for GILD is set to $79.0. It would indicate a potential upside of 12.09 % from firm’s close price.

The new coverage is welcomed by stock traders, as NASDAQ:GILD is right now trading 4.41% higher at $70.48 as of 8:05 AM New York time. Gilead Sciences shares have [From2] 0% over the past 200 days, while the S&P500 Index has added 6.00% for the same time.

According to data compiled by Thomson Reuters, Gilead Sciences (NASDAQ:GILD)’s stock is covered by 19 equity analysts across the Street, with 0 analysts giving it a Sell rating, 16 a Buy rating, while 9 consider it a Hold. The 12-month consensus target price for the stock is $111.05, which reflects an upside potential of 57.56% over the current price.

Institutional Ownership

Domini Social Investments Llc had the largest stake with ownership of 4,906 shares as of q2 2015 for 17.99% of the US long equity exposure. Cabot is another quite bullish investment manager who is possessing 147,130 shares of Gilead Sciences or 9.41% of their US long equity exposure. Moreover, Hollow Brook Wealth Management Llc have 8.91% of their US long equity exposure invested in the company for 190,499 shares. The Singapore-based fund Temasek Holdings (Private) Ltd revealed it had purchased a stake worth about 8.86% of the investment manager’s stock portfolio in Gilead Sciences. The Massachusetts-based fund Tekla Capital Management Llc is also positive about the stock, possessing 13.83M shares or 8.09% of their US long equity exposure.

Gilead Sciences (NASDAQ:GILD) Profile

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta.

Gilead Sciences (NASDAQ:GILD) traded up 4.41% on 23 June, hitting $70.48. A total of 28.96 million shares of the company’s stock traded hands. This is up from average of 7.92 million shares. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $88.85. The company has a market cap of $94.78 billion and a P/E ratio of 7.45.

Get the latest Gilead Sciences (NASDAQ:GILD) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Deutsche Bank Started Coverage on Gilead Sciences (NASDAQ:GILD) Stock with $79.0 TP appeared first on Octafinance.